Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | CASP3 | P42574 | 2/20 | 0.57 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353997 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29378420 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL30191581 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119339 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29401430 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL31675022 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29792126 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL118051 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| Water SCHEMBL21809391 | 0.99 | MDM4 (0.59) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL22636280 | 0.93 | MDM4 (0.59) | MDM4TP53CASP3TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| CN-117924431-A | Natural cyclopeptide zelkovamycins simplified substance and preparation method and application thereof | 北流市中医医院 | 2024-04-26 | — | — | CN | claimed |
| CN-110305042-A | N α-fluorenylmethyloxycarbonyl-N γ-(4,4- dimethyl -2,6- dioxo hexamethylene subunit) ethyl-butyric acid preparation method | 吉尔生化（上海）有限公司 | 2019-10-08 | — | — | CN | claimed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-117924431-A | Natural cyclopeptide zelkovamycins simplified substance and preparation method and application thereof | 北流市中医医院 | 2024-04-26 | — | — | CN | disclosed |
| US-11912794-B2 | Modulation of structured polypeptide specificity | Bicyclerd Limited (GB) | 2024-02-27 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-5866592-A | Fibrinogen receptor antagonist and pharmaceutical compositions comprising the same | NIPPON STEEL CORPORATION (JP) | 1999-02-02 | — | — | US | disclosed |
| EP-0846950-A2 | Peptides useful as internal standards for microsequencing and method for their use | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-06-10 | — | — | EP | disclosed |
| EP-0651883-B1 | PEPTIDES USEFUL AS INTERNAL STANDARDS FOR MICROSEQUENCING AND METHODS FOR THEIR USE | US HEALTH (US) | 1998-05-13 | — | — | EP | disclosed |
| EP-0800516-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1997-10-15 | — | — | EP | disclosed |
| WO-1997022589-A1 | BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS | GLAXO GROUP LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
| US-5589397-A | SIMULTANEOUSLY SEQUENCING INTERNAL STANDARD COMPRISING PEPTIDE CONSISTING OF UNNATURAL AMINO ACID RESIDUES AND UNKNOWN PEPTIDE IN SEQUENCER TO PRODUCE CHROMATOGRAM, COMPARING RETENTION TIMES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-12-31 | — | — | US | disclosed |
| WO-1996020172-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1996-07-04 | — | — | WO | disclosed |
| EP-0651883-A1 | PEPTIDES USEFUL AS INTERNAL STANDARDS FOR MICROSEQUENCING AND METHODS FOR THEIR USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002856-A1 | PEPTIDES USEFUL AS INTERNAL STANDARDS FOR MICROSEQUENCING AND METHODS FOR THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | MDM4 476/4885TP53 10/4885CASP3 3300/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | MDM4 1294/4885TP53 178/4885CASP3 3268/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | MDM4 2155/4885TP53 3262/4885CASP3 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.